BMJ 1999;319:958-964 ( 9 October )

General Practice

Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin

B S P Hellemons, general practitionera M Langenberg, general practitionera J Lodder, neurologistb F Vermeer, cardiologistc H J A Schouten, clinical biostatistitiand Th Lemmens, general practitionera J W van Ree, professora J A Knottnerus, professora

a Department of General Practice, University of Maastricht, P O Box 616, 6200 MD Maastricht, Netherlands, b Department of Neurology, University of Maastricht, c Department of Cardiology, University of Maastricht, d Department of Methodology and Statistics, University of Maastricht

Correspondence to: B S P Hellemons-Boode Bep.Hellemons{at}HAG.Unimaas.NL

Objective: To investigate the effectiveness of aspirin and coumarin in preventing thromboembolism in patients with non-rheumatic atrial fibrillation in general practice.
Design: Randomised controlled trial.
Participants: 729 patients aged >= 60 years with atrial fibrillation, recruited in general practice, who had no established indication for coumarin. Mean age was 75 years and mean follow up 2.7 years.
Setting: Primary care in the Netherlands.
Interventions: Patients eligible for standard intensity coumarin (international normalised ratio 2.5-3.5) were randomly assigned to standard anticoagulation, very low intensity coumarin (international normalised ratio 1.1-1.6), or aspirin (150 mg/day) (stratum 1). Patients ineligible for standard anticoagulation were randomly assigned to low anticoagulation or aspirin (stratum 2).
Main outcome measures: Stroke, systemic embolism, major haemorrhage, and vascular death.
Results: 108 primary events occurred (annual event rate 5.5%), including 13 major haemorrhages (0.7% a year). The hazard ratio was 0.91 (0.61 to 1.36) for low anticoagulation versus aspirin and 0.78 (0.34 to 1.81) for standard anticoagulation versus aspirin. Non-vascular death was less common in the low anticoagulation group than in the aspirin group (0.41, 0.20 to 0.82). There was no significant difference between the treatment groups in bleeding incidence. High systolic and low diastolic blood pressure and age were independent prognostic factors.
Conclusion: In a general practice population (without established indications for coumarin) neither low nor standard intensity anticoagulation is better than aspirin in preventing primary outcome events. Aspirin may therefore be the first choice in patients with atrial fibrillation in general practice.


Key messages

  • Studies have shown that patients with non-rheumatic atrial fibrillation may benefit from anticoagulation

  • This study in a general practice population found no benefit of standard or low dose anticoagulation on risk of stroke, systemic embolism, major haemorrhage, or vascular death when compared with aspirin

  • Hypertension and age were prognostic factors for event occurrence

  • Aspirin is the treatment of choice for preventing thromboembolism in primary care patients at low risk





© BMJ 1999

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • van Walraven, C., Hart, R. G., Connolly, S., Austin, P. C., Mant, J., Hobbs, F.D. R., Koudstaal, P. J., Petersen, P., Perez-Gomez, F., Knottnerus, J. A., Boode, B., Ezekowitz, M. D., Singer, D. E. (2009). Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators. Stroke 40: 1410-1416 [Abstract] [Full text]  
  • Andersen, L V, Vestergaard, P, Deichgraeber, P, Lindholt, J S, Mortensen, L S, Frost, L (2008). Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart 94: 1607-1613 [Abstract] [Full text]  
  • Wan, Y., Heneghan, C., Perera, R., Roberts, N., Hollowell, J., Glasziou, P., Bankhead, C., Xu, Y. (2008). Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review. Circ Cardiovasc Qual Outcomes 1: 84-91 [Abstract] [Full text]  
  • Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., Palareti, G. (2008). Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 160S-198S [Abstract] [Full text]  
  • Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N. (2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 257S-298S [Abstract] [Full text]  
  • Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., Manning, W. J. (2008). Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 546S-592S [Abstract] [Full text]  
  • Toyoda, K., Yasaka, M., Iwade, K., Nagata, K., Koretsune, Y., Sakamoto, T., Uchiyama, S., Gotoh, J., Nagao, T., Yamamoto, M., Takahashi, J. C., Minematsu, K., for the Bleeding with Antithrombotic Therapy (BAT), (2008). Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease: A Prospective, Multicenter, Observational Study. Stroke 39: 1740-1745 [Abstract] [Full text]  
  • Garwood, C. L, Corbett, T. L (2008). Use of Anticoagulation in Elderly Patients with Atrial Fibrillation Who Are at Risk for Falls. The Annals of Pharmacotherapy 42: 523-532 [Abstract] [Full text]  
  • Hart, R. G., Pearce, L. A., Aguilar, M. I. (2007). Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation. ANN INTERN MED 147: 590-592 [Full text]  
  • Hart, R. G., Pearce, L. A., Aguilar, M. I. (2007). Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. ANN INTERN MED 146: 857-867 [Abstract] [Full text]  
  • Writing Committee Members, , Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8: 651-745 [Full text]  
  • Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society . J Am Coll Cardiol 48: 854-906 [Full text]  
  • Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society . J Am Coll Cardiol 48: e149-e246 [Full text]  
  • Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA TASK FORCE MEMBERS, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC COMMITTEE FOR PRACTICE GUIDELINES, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257-e354 [Full text]  
  • Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA TASK FORCE MEMBERS, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC COMMITTEE FOR PRACTICE GUIDELINES, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: 700-752 [Full text]  
  • Authors/Task Force Members, , Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L., ACC/AHA (Practice Guidelines) Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 27: 1979-2030 [Full text]  
  • Cooper, N. J., Sutton, A. J., Lu, G., Khunti, K. (2006). Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.. Arch Intern Med 166: 1269-1275 [Abstract] [Full text]  
  • Bath, P. M.W., Zhao, L., Heptinstall, S. (2005). Current status of stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 7: C12-C18 [Abstract] [Full text]  
  • Emmerich, J., Le Heuzey, J.-Y., Bath, P. M.W., Connolly, S. J. (2005). Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. Eur Heart J Suppl 7: C28-C33 [Abstract] [Full text]  
  • O'Brien, C. L., Gage, B. F. (2005). Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation. JAMA 293: 699-706 [Abstract] [Full text]  
  • Reynolds, M. W., Fahrbach, K., Hauch, O., Wygant, G., Estok, R., Cella, C., Nalysnyk, L. (2004). Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation: A Systematic Review and Metaanalysis. Chest 126: 1938-1945 [Abstract] [Full text]  
  • Gage, B. F., van Walraven, C., Pearce, L., Hart, R. G., Koudstaal, P. J., Boode, B.S.P., Petersen, P. (2004). Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin. Circulation 110: 2287-2292 [Abstract] [Full text]  
  • Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., Hylek, E. (2004). The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 204S-233S [Abstract] [Full text]  
  • Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S. (2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 287S-310S [Abstract] [Full text]  
  • Singer, D. E., Albers, G. W., Dalen, J. E., Go, A. S., Halperin, J. L., Manning, W. J. (2004). Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 429S-456S [Abstract] [Full text]  
  • Snow, V., Weiss, K. B., LeFevre, M., McNamara, R., Bass, E., Green, L. A., Michl, K., Owens, D. K., Susman, J., Allen, D. I., Mottur-Pilson, C., the Joint AAFP/ACP Panel on Atrial Fibrillation, (2003). Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians. ANN INTERN MED 139: 1009-1017 [Abstract] [Full text]  
  • McNamara, R. L., Tamariz, L. J., Segal, J. B., Bass, E. B. (2003). Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography. ANN INTERN MED 139: 1018-1033 [Abstract] [Full text]  
  • Hart, R. G., Halperin, J. L., Pearce, L. A., Anderson, D. C., Kronmal, R. A., McBride, R., Nasco, E., Sherman, D. G., Talbert, R. L., Marler, J. R., for the Stroke Prevention in Atrial Fibrillation I, (2003). Lessons from the Stroke Prevention in Atrial Fibrillation Trials. ANN INTERN MED 138: 831-838 [Abstract] [Full text]  
  • Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41: 1633-1652 [Full text]  
  • van Walraven, C., Hart, R. G., Wells, G. A., Petersen, P., Koudstaal, P. J., Gullov, A. L., Hellemons, B. S. P., Koefed, B. G., Laupacis, A. (2003). A Clinical Prediction Rule to Identify Patients With Atrial Fibrillation and a Low Risk for Stroke While Taking Aspirin. Arch Intern Med 163: 936-943 [Abstract] [Full text]  
  • Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation 107: 1692-1711 [Full text]  
  • Rutten, F. H, Hak, E., Stalman, W. A., Verheij, T. J., Hoes, A. W (2003). Is treatment of atrial fibrillation in primary care based on thromboembolic risk assessment?. Fam Pract 20: 16-21 [Abstract] [Full text]  
  • van Walraven, C., Hart, R. G., Singer, D. E., Laupacis, A., Connolly, S., Petersen, P., Koudstaal, P. J., Chang, Y., Hellemons, B. (2002). Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation: An Individual Patient Meta-analysis. JAMA 288: 2441-2448 [Abstract] [Full text]  
  • Reis, S., Hermoni, D., Livingstone, P., Borkan, J. (2002). Integrated narrative and evidence based case report: Case report of paroxysmal atrial fibrillation and anticoagulation. BMJ 325: 1018-1020 [Full text]  
  • (2001). Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 22: 1852-1923  
  • Duxbury, B. McD., Poller, L. (2001). State-of-the-Art Review: The Oral Anticoagulant Saga: Past, Present, and Future. CLIN APPL THROMB HEMOST 7: 269-275 [Abstract]  
  • Fuster, V., Ryden, L. E., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Levy, S., McNamara, R. L., Prystowsky, E. N., Wann, L. S., Wyse, D. G., Gibbons, R. J., Antman, E. M., Alpert, J. S., Faxon, D. P., Fuster, V., Gregoratos, G., Hiratzka, L. F., Jacobs, A. K., Russell, R. O., Smith, S. C. Jr, Klein, W. W., Alonso-Garcia, A., Blomstrom-Lundqvist, C., De Backer, G., Flather, M., Hradec, J., Oto, A., Parkhomenko, A., Silber, S., Torbicki, A. (2001). ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 38: 1266-1266 [Full text]  
  • Cleland, J. G F, Kaye, G. C, Mant, J., Fitzmaurice, D., Murray, E., Lip, G. Y H, Hobbs, F D R., Peterson, G., Jackson, S., Stragliotto, E., Godtfredsen, J., Boysen, G., Petersen, P., Evans, A., Kalra, L., Cates, C., Taylor, F., Cohen, H., Ebrahim, S. (2001). Long term anticoagulation or antiplatelet treatment. BMJ 323: 233-233 [Full text]  
  • Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., Radford, M. J. (2001). Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870 [Abstract] [Full text]  
  • Gage, B. F., Fihn, S. D., White, R. H. (2001). Warfarin Therapy for an Octogenarian Who Has Atrial Fibrillation. ANN INTERN MED 134: 465-474 [Abstract] [Full text]  
  • Hart, R. G., Halperin, J. L. (2001). Atrial Fibrillation and Stroke : Concepts and Controversies. Stroke 32: 803-808 [Full text]  
  • Taylor, F C, Cohen, H, Ebrahim, S (2001). Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 322: 321-326 [Abstract] [Full text]  
  • Ansell, J., Hirsh, J., Dalen, J., Bussey, H., Anderson, D., Poller, L., Jacobson, A., Deykin, D., Matchar, D. (2001). Managing Oral Anticoagulant Therapy. Chest 119 : 22S-38S [Full text]  
  • Levine, M. N., Raskob, G., Landefeld, S., Kearon, C. (2001). Hemorrhagic Complications of Anticoagulant Treatment. Chest 119 : 108S-121S [Full text]  
  • Albers, G. W., Dalen, J. E., Laupacis, A., Manning, W. J., Petersen, P., Singer, D. E. (2001). Antithrombotic Therapy in Atrial Fibrillation. Chest 119 : 194S-206S [Full text]  
  • Cates, C. (2000). Care is required with cost effectiveness approach. BMJ 321: 449-449 [Full text]  
  • Hart, R. G., Pearce, L. A. (2000). Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation. ANN INTERN MED 132: 841-842 [Full text]  
  • Kalra, L., Yu, G., Perez, I., Lakhani, A., Donaldson, N. (2000). Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 320: 1236-1239 [Abstract] [Full text]  
  • Ellis, S. J, Hans, R., Mant, J., Fitzmaurice, D., Murray, E., Hobbs, R., Evans, A., Perez, I., Kalra, L., Rutten, F. H, Hak, E., Hoes, A. W, Rose, P E, Taylor, F. C., Ebrahim, S., Hellemons, B., Langenberg, M., van Ree, J., Knottnerus, A., Lodder, J., Vermeer, F., Schouten, H. (2000). Using anticoagulation or aspirin to prevent stroke. BMJ 320: 1008-1008 [Full text]  
  • Ansell, J. E., Weitz, J. I., Comerota, A. J. (2000). Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. ASH Education Book 2000: 266-284 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

Interesting
John Harley
bmj.com, 10 Oct 1999 [Full text]
Impressive Study
Andrew Batey
bmj.com, 13 Oct 1999 [Full text]
Interesting but small numbers
Martin Wilkinson
bmj.com, 14 Oct 1999 [Full text]
evidence is not neccessarily fact
Robert Fleetcroft
bmj.com, 14 Oct 1999 [Full text]
Misleading Conclusion
Mayer Brezis
bmj.com, 14 Oct 1999 [Full text]
Study does not have power to show that aspirin is as good as anticoagulation in this case
Jonathan Mant
bmj.com, 16 Oct 1999 [Full text]
PRIMARY PREVENTION OF ARTERIAL THROMBO-EMBOLISM IN NON- RHEUMATIC ATRIAL
Michael A James
bmj.com, 22 Oct 1999 [Full text]
Suspect conclusions could be damaging.
Jonathan D Dickson
bmj.com, 29 Oct 1999 [Full text]
Response
David Church
bmj.com, 2 Nov 1999 [Full text]
Effectiveness of anticoagulation for primary prevention of stroke in general practice
Andy Evans
bmj.com, 5 Nov 1999 [Full text]
Response
O Bertel
bmj.com, 10 Nov 1999 [Full text]
Potentially misleading
Gregory Y H Lip
bmj.com, 12 Nov 1999 [Full text]
Key messages may mislead primary care prescribers
Helen Park
bmj.com, 18 Nov 1999 [Full text]
Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care:
Frans Rutten
bmj.com, 4 Dec 1999 [Full text]
Aspirin or anticoagulation for non-rheumatic atrial fibrillation
Fiona C Taylor
bmj.com, 14 Dec 1999 [Full text]



Access jobs at BMJ Careers
Whats new online at Student 

BMJ